title: FGF-23 and vitamin D: don't shoot the messenger?
abstract: The discovery of fibroblast growth factor-23 (FGF-23) as a key regulator of phosphate and vitamin D metabolism has forced a rethink about the mineral and bone disorder of chronic kidney disease (CKD). FGF-23 powerfully predicts adverse cardiovascular outcomes in patients with CKD and an important question is whether treatment regimens should now be tailored to address FGF-23 levels in addition to those of calcium, phosphate, parathyroid hormone and vitamin D. Nevertheless, despite the known action of active vitamin D therapies to increase FGF-23, this should probably still form an important part of the management of patients with hyperparathyroidism and perhaps at low doses of essentially all patients with advanced renal disease.
authors.forename: Richard S
authors.initials: RS
authors.lastname: Fish
authors.forename: John
authors.initials: J
authors.lastname: Cunningham
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004872:Ergocalciferols / Q000627:therapeutic use*; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000378:metabolism*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male
chemical_list: D050071:Bone Density Conservation Agents; D004872:Ergocalciferols; C000717427:FGF23 protein, human; D006887:Hydroxycholecalciferols; D005346:Fibroblast Growth Factors; C084656:paricalcitol; D000089703:Fibroblast Growth Factor-23; C008088:alfacalcidol